腹腔镜远端胃癌根治术中加速康复外科对比常规护理的三年生存结局:GISSG1901随机临床试验
该多中心随机对照试验纳入527例局部进展期胃下部腺癌患者,比较加速康复外科(ERAS)与常规护理在腹腔镜远端胃癌根治术中的肿瘤学结局。ERAS组总体并发症更少(21.0% vs 30.4%,P=0.037),3年总生存(OS)和无病生存(DFS)均优于常规组(OS 86.56% vs 80.11%,P=0.025;DFS 79.57% vs 69.57%,P=0.027),尤其在III期患者中获益更明显。
要点
- ERAS可减少腹腔镜远端胃癌根治术后的总体并发症。
- ERAS改善3年OS和DFS,III期患者获益更显著。
- ERAS缩短术后住院时间和辅助化疗间隔,降低医疗费用。
核心结论
- 腹腔镜远端胃癌根治术中实施ERAS可减少总体并发症、缩短住院时间、降低医疗费用,并改善3年OS和DFS,尤其在III期胃癌患者中。
研究设计与样本
- 多中心、随机、对照试验,2019年4月4日至2020年3月18日从中国13个中心招募527例局部进展期胃下部腺癌患者。
- 主要终点为3年总生存(OS)和无病生存(DFS);次要终点包括并发症、死亡率、恢复情况、接受辅助化疗时间和医疗费用。
- 全分析集包括ERAS组186例和常规组184例,两组人口学与基线特征均衡。
主要发现
- ERAS组总体并发症发生率为21.0%,常规组为30.4%(P=0.037)。
- ERAS组和常规组的3年OS分别为86.56%和80.11%(log-rank P=0.025)。
- ERAS组和常规组的3年DFS分别为79.57%和69.57%(log-rank P=0.027)。
- III期患者中,ERAS组3年OS为79.41%,常规组为64.47%(log-rank P=0.046);3年DFS分别为70.59%和53.95%(log-rank P=0.046)。
- I期和II期患者中,两组3年OS和DFS相似(I期OS P=0.901、DFS P=0.859;II期OS P=0.421、DFS P=0.459)。
关键数值与推荐
- ERAS组总体并发症21.0% vs 常规组30.4%(P=0.037)。
- 3年OS:ERAS组86.56% vs 常规组80.11%(log-rank P=0.025)。
- 3年DFS:ERAS组79.57% vs 常规组69.57%(log-rank P=0.027)。
- III期3年OS:ERAS组79.41% vs 常规组64.47%(log-rank P=0.046)。
- III期3年DFS:ERAS组70.59% vs 常规组53.95%(log-rank P=0.046)。
临床怎么用
- 在腹腔镜远端胃癌根治术中可考虑实施ERAS以改善短期结局和长期生存。
- III期胃癌患者可能从ERAS中获得更显著的生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The efficacy of enhanced recovery after surgery (ERAS) to improve the prognosis of patients who undergo laparoscopic distal gastrectomy (LDG) for gastric cancer is uncertain. This randomized study compared oncological outcomes in LDG after ERAS or conventional care. BACKGROUND: At present, randomized controlled trials have confirmed that ERAS can improve the short-term clinical outcomes of patients undergoing LDG, but whether it improves survival has not been reported yet. METHODS: A multicenter, randomized, controlled trial was performed to compare oncological outcomes of ERAS versus conventional care in LDG. Between April 4, 2019 and March 18, 2020, 527 patients with locally advanced lower gastric adenocarcinoma were recruited from 13 centers in China. The primary endpoints were 3-year overall survival (OS) and disease-free survival (DFS). The secondary endpoints were complications, mortality, recovery, time of receiving adjuvant chemotherapy, and medical expenses. RESULTS: The full analysis set included 186 cases in the ERAS group and 184 in the conventional group, well balanced with respect to patient demographics and baseline characteristics (published before). Postoperative hospital stay and the interval before adjuvant chemotherapy were obviously shorter in the ERAS group compared with the conventional group as reported previously and with lower medical expenses. Compared with the conventional group, the ERAS group had fewer overall complications (21.0% vs 30.4%, respectively; P = 0.037). The median (interquartile range) follow-up for all cases was 42.17 (range: 3.12-48.50) months. The 3-year OS and DFS in the ERAS group and conventional group were 86.56% and 80.11% (log-rank P = 0.025), 79.57% and 69.57% (log-rank P = 0.027), respectively. In a subgroup analysis of stage I and II disease patients, 3-year OS and DFS were similar between the groups ( P = 0.901; P = 0.859 for stage I and P = 0.421; P = 0.459 for stage II). However, in the stage III disease, the ERAS group exhibited longer 3-year OS and DFS than the conventional group (79.41% vs 64.47% for OS, log-rank P = 0.046; 70.59% vs 53.95% for DFS, log-rank P = 0.046). CONCLUSIONS: Patients undergoing ERAS LDG had fewer overall complications, shorter hospital stays, decreased medical expenses, and improved 3-year OS and DFS rates, particularly in cases with stage III gastric cancer.
引用
- Tian Y, Cao S, Li L, et al. Three-year Survival Outcomes of Patients With Enhanced Recovery After Surgery Versus Conventional Care in Laparoscopic Distal Gastrectomy: The GISSG1901 Randomized Clinical Trial. Ann Surg. 2024. PMID: 39660451. doi:10.1097/SLA.0000000000006603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。